{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-24-000053","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2024-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.177462+00:00","generated_at":"2026-05-31T23:14:43.285653+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ligand acquires APEIRON for $100M, adds QARZIBA royalty; raises 2024 guidance","bullets":["Acquisition of APEIRON Biologics for $100M cash; up to $28M additional contingent consideration based on QARZIBA royalty thresholds by 2030/2034.","QARZIBA is approved in EU for high-risk neuroblastoma, marketed in >35 countries by Recordati; patent protection until 2034.","Transaction expected to close July 2024; subject to 30-day shareholder objection period and other customary conditions.","Ligand raises 2024 revenue guidance to $140M-$157M (from $130M-$142M) and core adjusted EPS to $5.00-$5.50 (from $4.25-$4.75).","Deal immediately accretive to EPS by ~$1.00 annualized; ~$0.50 impact in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-24-000053","json":"https://secwatch.observer/filing/0000886163-24-000053.json","markdown":"https://secwatch.observer/filing/0000886163-24-000053.md","text":"https://secwatch.observer/filing/0000886163-24-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000053/0000886163-24-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000053/lgnd-20240708.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:14:43.285653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}